LewisLi-YenHsuMDPhD(He/Him)

Pediatric Hematology & Oncology • Chicago, IL

Pediatric Anemia and Red Blood Cell Hematology

University of Illinois

Join to view full profile

Dr. Hsu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hsu's full profile

Already have an account?

Office
840 S. Wood St. MC856
University of Illinois, Pediatric Hematology Oncology
Chicago, IL 60612
Phone+1 312-996-6143

Fax+1 312-413-9484

Summary

Lewis Hsu, MD, PhD, is a pediatric hematologist with a career devoted to sickle cell disease, both clinical and translational research. Hsu developed a lifelong affinity for interdisciplinary collaboration during his education in Chemical Engineering and the combined MD-PhD (Biophysics). He has served in leadership of some of the largest pediatric sickle cell centers in the USA. His clinical and translational research in sickle cell disease includes the landmark STOP study of transfusion to reduce stroke risk in sickle cell, landmark studies of bone marrow transplantation to cure sickle cell disease, clinical research on pain management of patients hospitalized with sickle cell pain, and studies of inflammatory vasculopathy due to hemolysis in mouse models. During 25 years of experience in leadership of some of the largest sickle cell programs in the country, his immersion in “team science” led to over 70 scientific publications. His research in sickle cell disease also includes community health workers, implementation science, health education, and global community engagement. He co-authored the “Hope and Destiny” books for family education on sickle cell and provides training for community health workers for sickle cell disease with Sickle Cell Disease Association of America (SCDAA) and with a pilot project in Nigeria, and the training of Linkage Specialists can build upon this foundation. His experience in applying implementation science to sickle cell disease includes formal training from NIH TIDIRC program and applications to sickle cell disease in NIH sickle cell projects and by the European Union for sickle cell in Africa. He had leadership roles on care transitions, social determinants of health, and patient-centered outcomes in PCORI work and in the CHECK project under Centers for Medicaid and Medicare Innovation. His community engagement and volunteer service includes Chief Medical Officer of SCDAA and global experience in Nigeria and Brazil.

amazing sickle cell patient Billy Garrett Jr is elite college basketball player

video clip from Fox Sports "Inside Big East" published January 26, 2015

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1991 - 1994
Yale-New Haven Medical CenterResidency, Pediatrics, 1988 - 1991
University of RochesterPh.D., Biophysics, 1981 - 1988
University of Rochester School of Medicine and DentistryClass of 1988
Cornell UniversityB.S., Chemical Engineering, 1977 - 1981

Certifications & Licensure

IL State Medical License 2011 - 2026
DC State Medical License 2009 - 2013
MD State Medical License 2010 - 2012
VA State Medical License 2009 - 2012
PA State Medical License 1991 - 2010
GA State Medical License 1994 - 2003
CT State Medical License 1991 - 1991
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Chicago Magazine: Top Doctors Castle Connolly, 2014-2020
Lifetime Achievement Award Howard University Sickle Cell Center, 2019
America's Top Doctors Castle Connolly, 2014-2019
Orme Award for Academic-Community Partnership Patient Family-Centered Care Partners, 2018
Health Advancement Researcher Award Community Health Charities of Georgia, 1999
Join now to see all

Clinical Trials

Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence Start of enrollment: 2005 Aug 01
Completed
A Phase II Trial of Regadenoson in Sickle Cell Anemia Start of enrollment: 2013 Jul 01
Completed
Phase 2
Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment Start of enrollment: 2014 Dec 01
Completed
Phase 4
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease Start of enrollment: 2014 Sep 11
Completed
Phase 2
Sickle Cell Pro-Inflammatory Response to Interval Training Study Start of enrollment: 2018 Jan 02
Recruiting
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease Start of enrollment: 2023 Jun 08
Recruiting
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Hereditary Spherocytosis with Mitochondrial Retention, Increased Oxidative Stress, and Alterations to Bioactive Membrane Lipids.
Daniel R Principe, Paige Reilly, Sugasini Dhavamani, Angela Rivers, Robert Molokie
Journal of Pediatric Hematology/oncology. 2024-08-01
1 citations
DISPLACE study shows poor quality of transcranial doppler ultrasound for stroke risk screening in sickle cell anemia.
Kimberly A Davidow, Robin E Miller, Shannon M Phillips, Alyssa M Schlenz, Martina Mueller
Blood Advances. 2024-07-09
3 citations
Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry.
Franklin Njoku, Norma Pugh, Donald Brambilla, Barbara Kroner, Nirmish Shah
American Journal of Hematology. 2024-05-01

Journal Articles

A Phase 3 Trial of L-glutamine in Sickle Cell Disease
Rita Bellevue, Joseph L Lasky, Elliott P Vichinsky, Lewis L Hsu, Sharada Sarnaik, Lynne D Neumayr, Yutaka Niihara, Sophie Lanzkron, Ifeyinwa Osunkwo, Lance Sieger, Edu..., The New England Journal of Medicine
Clinical Trial Implementation and Recruitment: Lessons Learned from the Early Closure of a Randomized Clinical Trial
Peters-Lawrence MH, Bell MC, Hsu LL, Osunkwo I, Seaman P, Blackwood M, Guillaume E, Bellevue R, Krishnamurti L, Smith WR, Dampier CD, Minniti CP; Sickle Cell Disease C..., Contemp Clin Trials, 3/1/2012
Hydroxyurea makes inflammation "just right"?
Hsu LL, Blood, 2/23/2012
Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease.
Quinn CT, Stuart MJ, Kesler K, Ataga KI, Wang WC, Styles L, Smith-Whitley K, Wun T, Raj A, Hsu LL, Krishnan S, Kuypers FA, Setty Y, Rhee S, Key NS, Buchanan GR; on Beh..., Br J Haematol, 10/1/2011
Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: A phase III analgesic trial for hospitalized sickle cell patients wit...
Dampier CD, Smith WR, Kim HY, Wager CG, Bell MC, Minniti CP, Keefer J, Hsu L, Krishnamurti L, Mack AK, McClish D, McKinlay SM, Miller ST, Osunkwo I, Seaman P, Telen MJ..., Am J Hematol, 8/29/2011
Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial
Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, Hagar RW, Howard T, Nuss R, Okam MM, Tremonti CK, Berman B, Villella A, Krishnamurti L, Lanzkron S, Cast..., JAMA, 3/1/2011
Comparing Abstract Numerical and Visual Depictions of Risk in Survey of Parental Assessment of Risk in Sickle Cell Hydroxyurea Treatment
Patterson CA, Barakat LP, Henderson PK, Nall F, Westin A, Dampier CD, Hsu LL, J Ped Hem/Onc, 1/1/2011
Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease
Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, Buchanan GR, Bunin N, Dickerhoff R, Giller R, Haut PR, Horan J, Hsu LL, Kamani N, Levine JE, M..., Biol Blood Marrow Transplant, 2/1/2010
Peripheral Arterial Tonometry In Assessing Endothelial Dysfunction In Pediatric Sickle Cell Disease
Sivamurthy K, Dampier C, MacDermott ML, Meier M, Cahill M, Hsu LL, Ped Hem Onc, 11/1/2009
Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability
Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT, Blood, 4/1/2007
Physician-diagnosed asthma and acute chest syndrome: associations with NOS polymorphisms
Duckworth L., Hsu L., Feng H., Wang JW, Sylvester JE., Kissoon N, Sandler E., Lima E, Pediatr Pulmonol, 4/1/2007
Parents’ Assessment of Risk in Sickle Cell Disease Treatment with Hydroxyurea
Meyappan J, Lampl M, Hsu LL, J Pediatr Hematol Oncol, 12/1/2005
Alpha Thalassemia Is Associated With Decreased Risk Of Abnormal TCD In Children With Sickle Cell Anemia
Hsu LL, Miller ST, Kutlar A, Wright E, Wang W, Pegelow CH, Driscoll C, Hurlet A, Woods G, Elsas L, Embury S, Adams R for the Stroke Prevention Trial (STOP) and the Coo..., J Ped Hem/Onc, 8/1/2003
Risk-resistance adaptation model for caregivers and their children with sickle cell syndromes
Brown RT, Lambert R, Devine D, Baldwin K, Casey R, Doepke K, Ievers CE, Hsu L, Buchanan I, Eckman J, Ann Behav Med, 1/1/2000
Impact of Bone Marrow Transplantation for Symptomatic Sickle Cell Disease: Long-Term Follow-up Evaluations
Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, Buchanan GR, Rogers ZR Dinndorf P, Davies SC, Roberts IAG, Dickerhoff R, Yeager AM, Hsu L, Kurtzbe..., Blood, 1/1/2000
Transfusion Prevents First Stroke in Children with Sickle Cell Anemia and Abnormal Transcranial Doppler: The STOP Trial
Adams RJ, McKie VC, Hsu LL, Files B. Vichinsky E. Pegelow C. Abboud M. Gallagher D. Kutlar A. Nichols FT. Bonds DR. Brambilla D, N Engl J Med, 7/1/1998
Join now to see all